Product Description
Levocabastine is a synthetic piperidine derivative with antihistamine properties. Levocabastine is a second generation histamine-1 receptor antagonist. When applied locally into the eye as a topical solution, this agent reduces itching, rhinorrhea and symptoms of allergic rhinitis or conjunctivitis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Levocabastine)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Ophthalmic, Nasal
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Belgium | Canada | Chile | Colombia | Czech | Denmark | Egypt | Finland | France | Germany | Greece | Iceland | Ireland | Israel | Italy | Korea | Lebanon | Luxembourg | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Portugal | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Ukraine | United Arab Emirates | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Spain
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Conjunctivitis, Allergic|Rhinitis, Allergic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2025-521230-29-00 |
2025-521230-29-00 | P3 |
Not yet recruiting |
Conjunctivitis, Allergic |
2029-09-01 |
|||
2024-515717-17-00 |
T502-SIT-073 | P3 |
Active, not recruiting |
Rhinitis, Allergic|Conjunctivitis, Allergic |
2025-06-13 |
2025-05-02 |
Treatments |